

## Sofosbuvir-Velpatasvir

Express Scripts
Prior Authorization
Phone 1-844-424-8886
Fax 1-877-251-5896

To start your Part D Coverage Determination request, you (or your representative or your doctor or other prescriber) should contact Express Scripts, Inc (ESI):

- You may Call ESI at 1-844-424-8886, 24 hours a day, 7 days a week, TTY users: 1-800-716-3231
- You may Fax your request to: 1-877-251-5896 (Attention: Medicare Reviews)
- You may also send your request via email to: <a href="mailto:medicarepartdparequests@express-scripts.com">medicarepartdparequests@express-scripts.com</a>

N	Member's	s Last N	ame: Member's First Name:				
5	SCAN ID	numbe	r: Date of Birth:				
F	Prescribe	er's Nam	ne: Contact Person:				
(	Office pho	one:	Office Fax:				
	Medicat	ion:	Diagnosis:				
	SECTIO	DN A	Please answer the following questions				
1.	$\theta$ Yes	θ Νο	Is the indication or diagnosis for the treatment of chronic hepatitis C in HCV genotype 1a 1b, 2, 3, 4, 5, or 6 infected patients?				
2.	$\theta$ Yes	θ Νο	Has the member's HCV infection been confirmed via detectable serum hepatitis C virus RNA by quantitative assay?				
3.	B. Please document the HCV RNA Level:						
4.	θYes	θ Νο	Will Epclusa be used concomitantly with P-gp inducers or moderate to potent CYP inducers (e.g., rifampin, St. John's wort, carbamazepine, etc.)?				
5.	$\theta$ Yes	θ Νο	Is the prescription written or recommended by an Infectious Disease Specialist, Gastroenterologist, or Hepatologist?				

<ul> <li>θ Yes θ No Genotype 2</li> <li>θ Yes θ No Genotype 3</li> <li>θ Yes θ No Genotype 4</li> <li>θ Yes θ No Genotype 5</li> <li>θ Yes θ No Genotype 6</li> <li>7. θ Yes θ No Does the member have decompensated cirrhosis (Child-Pugh B or C)?</li> <li>8. θ Yes θ No Will Epclusa be used in combination with ribavirin?</li> <li>9. θ Yes θ No Has the member failed prior sofosbuvir- or NS5A-based treatment prior to the initiation of Epclusa?</li> <li>10. θ Yes θ No Is the member ineligible for ribavirin?</li> <li>Please document the symptoms and/or any other information important to this review:</li> </ul> PHYSICIAN SIGNATURE DATE	б.	vvnat is θ Yes	tne mer θ No	mber's nepatitis C virus genotype?  Genotype 1a or 1b	
<ul> <li>θ Yes θ No Genotype 3</li> <li>θ Yes θ No Genotype 4</li> <li>θ Yes θ No Genotype 5</li> <li>θ Yes θ No Genotype 6</li> </ul> 7. θ Yes θ No Does the member have decompensated cirrhosis (Child-Pugh B or C)?  8. θ Yes θ No Will Epclusa be used in combination with ribavirin?  9. θ Yes θ No Has the member failed prior sofosbuvir- or NS5A-based treatment prior to the initiation of Epclusa?  10. θ Yes θ No Is the member ineligible for ribavirin?  Please document the symptoms and/or any other information important to this review:  SECTION B  Physician Signature				<b>,</b> ,	
<ul> <li>θ Yes θ No Genotype 4</li> <li>θ Yes θ No Genotype 5</li> <li>θ Yes θ No Genotype 6</li> <li>7. θ Yes θ No Does the member have decompensated cirrhosis (Child-Pugh B or C)?</li> <li>8. θ Yes θ No Will Epclusa be used in combination with ribavirin?</li> <li>9. θ Yes θ No Has the member failed prior sofosbuvir- or NS5A-based treatment prior to the initiation of Epclusa?</li> <li>10. θ Yes θ No Is the member ineligible for ribavirin?</li> <li>Please document the symptoms and/or any other information important to this review:</li> </ul> SECTION B Physician Signature				· · · · · · · · · · · · · · · · · · ·	
<ul> <li>θ Yes θ No Genotype 5</li> <li>θ Yes θ No Does the member have decompensated cirrhosis (Child-Pugh B or C)?</li> <li>θ Yes θ No Will Epclusa be used in combination with ribavirin?</li> <li>θ Yes θ No Has the member failed prior sofosbuvir- or NS5A-based treatment prior to the initiation of Epclusa?</li> <li>θ Yes θ No Is the member ineligible for ribavirin?</li> <li>Please document the symptoms and/or any other information important to this review:</li> </ul> SECTION B Physician Signature				<b>,</b> ,	
<ul> <li>θ Yes θ No Genotype 6</li> <li>7. θ Yes θ No Does the member have decompensated cirrhosis (Child-Pugh B or C)?</li> <li>8. θ Yes θ No Will Epclusa be used in combination with ribavirin?</li> <li>9. θ Yes θ No Has the member failed prior sofosbuvir- or NS5A-based treatment prior to the initiation of Epclusa?</li> <li>10. θ Yes θ No Is the member ineligible for ribavirin?</li> <li>Please document the symptoms and/or any other information important to this review:</li> <li>SECTION B</li> <li>Physician Signature</li> </ul>				• •	
<ul> <li>8. θ Yes θ No Will Epclusa be used in combination with ribavirin?</li> <li>9. θ Yes θ No Has the member failed prior sofosbuvir- or NS5A-based treatment prior to the initiation of Epclusa?</li> <li>10. θ Yes θ No Is the member ineligible for ribavirin?</li> <li>Please document the symptoms and/or any other information important to this review:</li> <li>SECTION B Physician Signature</li> </ul>					
<ul> <li>9. θ Yes θ No Has the member failed prior sofosbuvir- or NS5A-based treatment prior to the initiation of Epclusa?</li> <li>10. θ Yes θ No Is the member ineligible for ribavirin?</li> <li>Please document the symptoms and/or any other information important to this review:</li> <li>SECTION B Physician Signature</li> </ul>	7.	$\theta$ Yes	θ Νο	Does the member have decompensated cirrhosis (Child-Pugh B or C)?	
of Epclusa?  10. θ Yes θ No Is the member ineligible for ribavirin?  Please document the symptoms and/or any other information important to this review:  SECTION B  Physician Signature	8.	$\theta$ Yes	θ Νο	Will Epclusa be used in combination with ribavirin?	
Please document the symptoms and/or any other information important to this review:  SECTION B  Physician Signature	9.	θYes	θ Νο		o the initiation
SECTION B Physician Signature	10.	$\theta$ Yes	θ Νο	Is the member ineligible for ribavirin?	
		Please d	docume	ent the symptoms and/or any other information important to this	review:
	-				
		SECTIO	M D	Dhyaician Signature	
PHYSICIAN SIGNATURE DATE		SECTION	JN D	<u>Physician Signature</u>	
PHYSICIAN SIGNATURE DATE					
PHYSICIAN SIGNATURE DATE					
PHYSICIAN SIGNATURE DATE					
			F	PHYSICIAN SIGNATURE DATE	

## **FAX COMPLETED FORM TO: 1-877-251-5896**

Our response time for prescription drug coverage standard requests is 72 hours. If you or your prescriber believe that waiting 72 hours for a standard decision could seriously harm your life, health, or ability to regain maximum function, you can ask for an expedited (fast) decision. If your prescriber indicates that waiting 72 hours could seriously harm your health, we will automatically give you a decision within 24 hours. If you do not obtain your prescriber's support for an expedited request, we will decide if your case requires a fast decision. You cannot request an expedited coverage determination if you are asking us to pay you back for a drug you already received. View our formulary and Prior Authorization criteria online at <a href="http://www.villagehealthca.com">http://www.villagehealthca.com</a>